A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers

Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer

(2013) M. Shiota et al.   CANCER RESEARCH

Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo

(2012) B Gibert et al.   BRITISH JOURNAL OF CANCER

Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27

(2010) Han-Shui Hsu et al.   CANCER

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion

(2008) Jürgen Hummel et al.   PHARMACEUTICAL STATISTICS